We therefore sought to improve the EwS therapy by combining the sgRUVBL1 with a BET inhibitor JQ1 (a BRD4 bromodomain inhibitor),[27] which has been reported to inhibit the expression of MYC through targeting its super‐enhancer[28] and demonstrated to suppress EwS tumors in animals.[29] Our results showed that, compared to the control tumors (gray), treatment with either JQ1 (green; 40 mg/kg/day) or sgRUVBL1 (blue) could reduce the A673 EwS tumor growth in the NSG xenograft model (Figure 6A,B). Here, MYC is linked to neoplasm.